Pfizer UK removes sales incentives for anti-infectives

  28 September 2019

Pfizer UK has changed how it incentivises its anti-infectives field-force under the drug giant’s commitment to the fight against antimicrobial resistance (AMR).

All sales have been ‘de-linked’ from its anti-infectives (AI) field-force incentives, with the focus now on measuring management-based objectives (MBOs) centering on generating access to medicines and promoting the appropriate use of antibiotics.

Further reading: PharmaTimes
Author(s): Pharmatimes
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!